


Rossari Biotech Ltd.



Rossari Biotech Ltd.

Robust product launch pipeline will drive future growth

CMP INR 841	Target INR 982	Potential Upside 16.8%	Market Cap (INR Mn) INR 46,385	Recommendation BUY	Sector Specialty Chemicals
-----------------------	--------------------------	----------------------------------	--	------------------------------	--------------------------------------


Result Highlights of Q1FY24:

- Rossari Biotech's consolidated revenue stood at INR 4,106 Mn for Q1FY24 which grew by 1% on a QoQ basis (-5.5% YoY) due to muted performance from subsidiaries and stable exports. On a standalone basis, revenue stood at INR 2,583 Mn (-2% QoQ/+10.5% YoY). The company reported steady numbers during the quarter despite weak macroeconomic environment.
- The consolidated EBITDA for the quarter stood flat at INR 577 Mn on a YoY basis and grew 5.8% on a QoQ basis. The EBITDA margin during the quarter stood at 14.1% as compared to 13.3% in Q1FY23 translating to an increase of 78bps YoY and 65 bps QOQ from 13.4% in Q4FY23. Improvement in margin is mainly attributable to efficient management of raw material price volatility and focus on high margin products.
- For Q1FY24, Rossari reported a flat net profit of INR 292 Mn (2.0% YoY, 1.2% QoQ). The quarter's PAT margins also remained at 7.1% (+53 bps YoY, -1 bp QoQ).

MARKET DATA

Shares outs (mn)	55
Equity Cap (INRmn)	110
Mkt Cap (INRmn)	46,385
52 Wk H/L (INR)	1051/536.1
Volume Avg (3m K)	164.6
Face Value (INR)	2
Bloomberg Code	ROSSARI IN

SHARE PRICE PERFORMANCE



MARKET INFO

SENSEX	66,527
NIFTY	19,753

SHARE HOLDING PATTERN (%)

Particulars	Jun-23	Mar-23	Dec 22
Promoters	68.4	68.4	68.4
FIIIs	6.1	7.5	8.6
DIIIs	17.7	15.1	14.1
Others	7.7	9.0	8.9
Total	100.0	100.0	100.0

Key Financials

INR millions	FY21	FY22	FY23	FY24E	FY25E
Revenue	7,093	14,830	16,559	18,501	21,880
EBITDA	1,231	1,834	2,230	2,579	3,683
PAT	800	977	1,073	1,368	2,166
EPS (INR)	15.47	17.70	19.38	24.80	39.27
EBITDA Margin (%)	17.3%	12.4%	13.5%	13.9%	16.8%
NPM (%)	11.3%	6.6%	6.5%	7.4%	9.9%

Source: Company data, KRChoksey Research

An overall revenue growth, HPPC segment disappoints:

- The HPPC segment witnessed a growth of 7% on QoQ and a de-growth of 11% YoY basis and contributed 68.9% to the total revenue, the revenues from this segment stood at INR 2,829 Mn. During the quarter, the HPPC segment showed a stable performance, even with weak demand in key domestic industries. The positive performance can be attributed to introduction and contribution of new product lines. These new products resulted in offsetting the softer demand in existing industries and contributed to the segment's overall success during the quarter. The performance of the HPPC segment is also affected by the shutdown of the plant due to the implementation of SAP S/4.
- TSC contribution to revenue remained flat on a QoQ basis at 24.2% the revenue from TSC segment stood at INR 993 Mn in Q1FY24 as compared to INR 985 Mn in Q4FY23. The muted performance in this segment is attributable to destocking in the global textile chemicals industry.
- AHN segment witnessed a reduction in revenue on a QoQ basis at -32.9% whereas on a YoY basis the same increased by 17% and stood at INR 285 Mn. The revenue contribution de-grew on a quarterly basis and stood at 6.9% in Q1FY24 as compared to 10.5% in Q4FY23. The AHN segment typically experiences a weak performance during the first quarter of the fiscal year.

Acquisitions of subsidiary, new product launches augurs well for the growth:

- The company has completed the acquisition of the additional 16% stake in Tristar, making it a 100% wholly-owned company. These inorganic acquisitions will further augment the presence in specialty chemical and expanding revenue streams. This will also extend manufacturing capabilities, enabling production of a wider range of products and meeting increased demands.

R&D:

- In HPPC, the R&D team developed essential ingredients for Pharma API and other industries. For Institutional Chemicals, they focused on creating new products for Indian Railways. In AHN, the R&D team is working on smart and sustainable aquaculture solutions, benefiting farmers in areas like probiotics, feed additives, disinfectants, and pond management technology. Additionally, the company implemented SAP S/4 Hana on Private Cloud to streamline operations across all 6 Group Companies. These initiatives showcase the company's commitment to innovation and growth.

Rossari Biotech Ltd.

Key Concall Highlights:

1. In Q1FY24, HPPC generated revenues of INR 2,829 Mn which accounted for 68.9% of total company's revenue. The TSC business contributed INR 993 Mn, accounting for 24.2% of the total company's revenue. While, AHN contributed INR 283 Mn contributing to 6.9% of the company's consolidated total revenue.
2. During the quarter, the HPPC segment demonstrated a stable performance, even with weaker demand in key domestic industries.
3. The addition of new product lines played a crucial role in supporting the overall performance of the segment.
4. The TSC segment's performance remained steady, but its growth was affected by substantial inventory destocking observed in the global markets.
5. The management expects the situation to improve in coming quarters with current inventory being cleared and fresh inventory being stocked.
6. The AHN segment, there was a decline in performance compared to the previous quarter. However, it still showed YoY growth. Generally, first quarter is generally considered a soft quarter.
7. Overall, despite some challenges in certain segments, the company is optimistic about its future performance.
8. The manages anticipates a revenue growth of ~12-14% for FY24E and stable EBITDA margins.

Valuation

Currently, the stock is trading at a PE multiples of 33.9x / 21.4x based on our FY24E / FY25E EPS estimates, respectively. We are positive on R&D strength of Rossari Biotech Ltd which has a major focus on developing new products for its long term business growth. We will continue to observe the margin performance as a key monitorable in the upcoming quarters. We estimate PAT to grow at 42.1% CAGR over FY23-25E with EBITDA margin range of 14% - 17%. We retain our target price at INR 982/share (P/E multiple 25x to FY25E EPS) and retain our BUY recommendation on the stock (upside: 16.8%)

Q1FY24 Result Analysis

Particulars (INR mn)	Q1FY24	Q1FY23	YoY	Q4FY23	QoQ
Revenue from operations	4,106	4,347	-5.5%	4,064	1.0%
COGS	2,895	3,106	-6.8%	2,863	1.1%
Gross Profit	1,211	1,241	-2.4%	1,201	0.8%
Gross Margin (%)	29.49%	28.55%	94bps	29.56%	-7bps
Employee benefits expense	245	235	4.3%	268	-8.4%
Other expenses	388	428	-9.4%	388	0.0%
EBITDA	577	577	0.0%	545	5.9%
EBITDA Margin (%)	14.1%	13.3%	78bps	13.4%	65bps
Depreciation and amortisation expense	141	153	-7.9%	160	-11.9%
EBIT	436	424	2.9%	385	13.3%
Finance costs	63	51	24.4%	43	45.3%
Other income	22	7	194.4%	28	-22.0%
Share of profit from JV/associates	0	6	-100.0%	2	-100.0%
Profit before tax	395	387	2.1%	372	6.3%
Total tax expense	102	100	2.2%	83	24.1%
Profit for the period	293	287	2.0%	289	1.2%
PAT Margin (%)	7.13%	6.60%	53bps	7.11%	1bps
EPS	5.30	5.21	1.7%	5.25	1.0%

Rossari Biotech Ltd.

QUARTERLY SEGMENT PERFORMANCE

Segment-wise Revenue (INRmn)	Q1FY23	Q2FY23	Q3FY23	Q4FY23	Q1FY24
HPPC*	3165	3033	2712	2654	2829
TSC	939	919	895	985	993
AHN	243	302	286	425	285
Total	4347	4254	3893	4064	4106
Segment-wise Growth YoY (%)					
HPPC*	139%	28%	-8%	-13%	-11%
TSC	26%	-16%	-19%	-10%	6%
AHN	1%	-22%	20%	67%	17%
Segment-wise Contribution (%)					
HPPC*	73%	71%	70%	65%	69%
TSC	22%	22%	23%	24%	24%
AHN	6%	7%	7%	10%	7%

Source: Company data, KRChoksey Research

SEGMENT-WISE REVENUE ESTIMATES – CONSOLIDATED BASIS

Revenue Model (INRmn)	FY21	FY22	FY23	FY24E	FY25E
HPPC	3994	9661	11564	12596	14922
TSC	2521	4047	3737	4381	4942
AHN	583	1121	1256	1524	2016
Segment-wise Growth (%)					
HPPC	42.2%	88.0%	26.2%	20.0%	20.0%
TSC	-3.9%	50.0%	-14.6%	15.0%	15.0%
AHN	2.5%	80.0%	19.8%	25.0%	26.0%
Segment-wise Contribution (%)					
HPPC	60.0%	65.1%	69.8%	68.1%	68.2%
TSC	33.4%	27%	23%	24%	22.6%
AHN	7.0%	8%	8%	8%	9.2%

Source: Company data, KRChoksey Research

Rossari Biotech Ltd.

Consolidated Financial Statements

Income Statement (INR mn)	FY21	FY22	FY23	FY24E	FY25E
Revenue from operations	7,093	14,830	16,559	18,501	21,880
Total Raw material costs	4,622	11,050	11,713	13,068	14,901
Gross Profit	2,472	3,779	4,846	5,433	6,978
Total expenses	1,241	1,945	2,615	2,854	3,295
EBITDA	1,231	1,834	2,230	2,579	3,683
Dep & Amort Exps	228	481	629	590	640
EBIT	1,002	1,354	1,601	1,988	3,043
Finance costs	30	127	223	244	241
Other income	92	120	55	84	85
Profit before tax	1,064	1,347	1,433	1,828	2,888
Total tax expense	268	386	370	461	722
Net Profit	800	977	1,073	1,368	2,166
Diluted EPS	15.47	17.70	19.38	24.80	39.27

Source: Company data, KRChoksey Research

Balance Sheet (INR mn)	FY21	FY22	FY23	FY24E	FY25E
Fixed Assets	1,682	3,480	3,267	3,345	3,373
Intangible Assets	134	2,605	2,730	2,562	2,393
Investments	0	359	512	512	512
Loans and other assets	229	99	92	103	122
Trade receivables	1,441	3,049	3,537	3,802	4,196
Inventories	954	1,899	1,885	2,027	2,218
Cash and cash equivalent	883	524	1,246	2,506	4,556
Other Assets	291	553	407	452	528
Total Assets	5,613	12,567	13,676	15,308	17,898
Equity Capital	104	110	110	110	110
Reserves	3,984	7,942	9,041	10,374	12,484
Shareholders Equity	4,088	8,052	9,152	10,484	12,594
Trade Payables	1,311	1,862	1,852	2,069	2,398
Current liabilities	182	1,069	1,599	1,666	1,789
Non Current liabilities	13	1,540	1,010	1,019	1,034
Provisions	19	45	62	70	82
Total Liabilities	5,613	12,567	13,676	15,308	17,898

Source: Company data, KRChoksey Research

Cash Flow Statement (INR mn)	FY21	FY22E	FY23	FY24E	FY25E
Operating Cash Flow	478	294	1,524	1,955	2,761
Investing Cash Flow	-372	-2,989	-1,809	-416	-415
Financing Cash Flow	-246	2,918	609	-279	-296
Net Inc/Dec in cash equivalents	-140	223	324	1,260	2,050
Opening Balance	292	152	375	698	1,958
Closing Balance Cash & Cash Eq.	152	375	698	1,958	4,008

Source: Company data, KRChoksey Research

Key Ratios	FY21	FY22	FY23	FY24E	FY25E
EBITDA Margin (%)	17.3%	12.4%	13.5%	13.9%	16.8%
Net Profit Margin (%)	11.3%	6.6%	6.5%	7.4%	9.9%
RoE (%)	23.0%	16.1%	12.5%	13.9%	18.8%
ROA (%)	15.5%	10.7%	8.2%	9.4%	13.0%
RoCE (%)	24.4%	14.1%	15.7%	17.2%	22.2%
Debt/Equity	0.0X	0.0X	0.1X	0.1X	0.1X

Source: Company data, KRChoksey Research

Rossari Biotech Ltd.

Rossari Biotech Ltd.				Rating Legend (Expected over a 12-month period)	
Date	CMP (INR)	TP (INR)	Recommendation	Our Rating	Upside
01-Aug-23	841	982	BUY	Buy	More than 15%
03-May-23	689	982	BUY	Accumulate	5% – 15%
10-Feb-23	690	974	BUY	Hold	0 – 5%
10-Aug-22	935	1,252	BUY	Reduce	-5% – 0
24-May-22	887	1,252	BUY	Sell	Less than – 5%
16-Feb-22	1,043	1,456	BUY		

ANALYST CERTIFICATION:

*I, Abhishek Agarwal (CA, CFA L3 cleared), Research Analyst, author and the name subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect my views about the subject issuer(s) or securities. I also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

*Terms & Conditions and other disclosures:

*KRChoksey Shares and Securities Pvt. Ltd (hereinafter referred to as KRCSPL) is a registered member of National Stock Exchange of India Limited and Bombay Stock Exchange Limited. KRCSPL is a registered Research Entity vide SEBI Registration No. INH00001295 under SEBI (Research Analyst) Regulations, 2014. KRCSPL Register with CDSL Registration No IN-DP-425-2019.

*The information and opinions in this report have been prepared by KRCSPL and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of KRCSPL. While we would endeavor to update the information herein on a reasonable basis, KRCSPL is not under any obligation to update the information. Also, there may be regulatory, compliance or other reasons that may prevent KRCSPL from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or KRCSPL policies, in circumstances where KRCSPL might be acting in an advisory capacity to this company, or in certain other circumstances.

*This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. KRCSPL will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. KRCSPL accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. Our employees in sales and marketing team, dealers and other professionals may provide oral or written market commentary or trading strategies that reflect opinions that are contrary to the opinions expressed herein, in reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest.

*We submit that no material disciplinary action has been taken on KRCSPL and its associates (Group Companies) by any Regulatory Authority impacting Equity Research Analysis activities.

*KRCSPL prohibits its associate, analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analyst covers.

*KRCSPL or its associates (Group Companies) collectively or its research analyst, or relatives do not hold any financial interest/beneficial ownership of more than 1% (at the end of the month immediately preceding the date of publication of the research report) in the company covered by Analyst, and has not been engaged in market making activity of the company covered by research analyst.

*It is confirmed that, I, Abhishek Agarwal Research Analyst of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months. Compensation of our Research Analysts is not based on any specific brokerage service transactions.

*KRCSPL or its Associates (Group Companies) have not managed or co-managed public offering of securities for the subject company in the past twelve months.

*KRCSPL or its associates (Group Companies) collectively or its research analyst, or relatives might have received any commission/compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of brokerage services or specific transaction or for products and services other than brokerage services.

*KRCSPL or its associates (Group Companies) collectively or its research analyst, or relatives might have received any commission/compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report other than investment banking or merchant banking or brokerage services from the subject company

*KRCSPL encourages the practice of giving independent opinion in research report preparation by the analyst and thus strives to minimize the conflict in preparation of research report. KRCSPL or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither KRCSPL nor Research Analysts his associate or his relative, have any material conflict of interest at the time of publication of this report.

*It is confirmed that, Abhishek Agarwal, Research Analyst do not serve as an officer, director or employee of the companies mentioned in the report.

*KRCSPL or its associates (Group Companies) or its research analyst has may been engaged in market making activity for the subject company.

*This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other Jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject KRCSPL and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform them of and to observe such restriction.

*Please send your feedback to research.insti@krchoksey.com

*Visit us at www.krchoksey.com

*KRChoksey Shares and Securities Pvt. Ltd.

*CIN-U67120MH1997PTC108958

*Registered Office:

*1102, Stock Exchange Tower, Dalal Street, Fort, Mumbai – 400 001.

*Phone: 91-22-6633 5000; Fax: 91-22-6633 8060

*Corporate Office: Abhishek, 5th Floor, Link Road, Andheri (W), Mumbai – 400 053. Phone: 91-22-6696 5555; Fax: 91-22-6691 9576